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Background-—Higher heart rate has been associated with an adverse prognosis, but most prior studies focused on individuals with
known cardiovascular disease or examined a limited number of outcomes. We sought to examine the association of baseline heart
rate with both fatal and nonfatal outcomes during 2 decades of follow-up.
Methods and Results-—Our study included 4058 Framingham Heart Study participants (mean age 55 years, 56% women). Cox
models were performed with multivariable adjustment for clinical risk factors and physical activity. A total of 708 participants
developed incident cardiovascular disease (303 heart failure, 343 coronary heart disease, and 216 stroke events), 48 received a
permanent pacemaker, and 1186 died. Baseline heart rate was associated with incident cardiovascular disease (hazard ratio [HR]
1.15 per 1 SD [11 bpm] increase in heart rate, 95% CI 1.07 to 1.24, P=0.0002), particularly heart failure (HR 1.32, 95% CI 1.18 to
1.48, P<0.0001). Higher heart rate was also associated with higher all-cause (HR 1.17, 95% CI 1.11 to 1.24, P<0.0001) and
cardiovascular mortality (HR 1.18, 95% CI 1.04 to 1.33, P=0.01). Spline analyses did not suggest a lower threshold beyond which
the beneﬁt of a lower heart rate abated or increased. In contrast, individuals with a higher heart rate had a lower risk of requiring
permanent pacemaker placement (HR 0.55, 95% CI 0.38 to 0.79, P=0.001).
Conclusions-—Individuals with a higher heart rate are at elevated long-term risk for cardiovascular events, in particular, heart
failure, and all-cause death. On the other hand, a higher heart rate is associated with a lower risk of future permanent pacemaker
implantation. (J Am Heart Assoc. 2014;3:e000668 doi: 10.1161/JAHA.113.000668)
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higher heart rate has been associated with worse
clinical outcomes,
1,2 particularly in individuals with
existing cardiovascular disease.
3,4 The underlying mecha-
nism of this association is not well understood: higher heart
rates may reﬂect underlying autonomic dysfunction and
sympathetic overactivity,
5,6 although direct effects of heart
rate on atherosclerosis
7 and myocardial energetics may
also contribute.
8 Speciﬁc pharmacologic lowering of heart
rate using the If channel inhibitor Ivabradine on background
b-blocker therapy has been associated with decreased
cardiovascular events in patients with chronic systolic heart
failure.
9
Prior studies have focused largely on fatal out-
comes
1,2,10,11 and have had relatively short durations of
follow-up. In previous studies, the association of heart rate
with events is often attenuated by adjustment for clinical
characteristics.
12–14 Further, analyses based on individuals
with existing cardiovascular disease can be confounded by
the use of b-blockers or other heart rate–slowing medica-
tions.
10,15 Thus, we examined the association of heart rate
with a full range of cardiovascular outcomes, in a large
community-based cohort that has been followed for 2
decades. Speciﬁcally, we sought to examine the following
outcomes: incident cardiovascular disease, including heart
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ORIGINAL RESEARCHfailure, coronary heart disease, and stroke, in addition to all-
cause mortality and future need for pacemaker implantation.
We restricted our analyses to prospectively adjudicated
events and accounted for numerous potential confounders
including physical activity.
Methods
Study Sample
The Framingham Heart Study (FHS) original and offspring
cohorts were recruited in 1948 and 1971, respectively, and
have since been followed with serial examinations.
16,17 A total
of 5420 participants attended the original cohort 20th exam-
ination (1986–1990, n=1401) or the offspring fourth examina-
tion (1987–1991, n=4019). Of this group, a total of 1361
participants were excluded from this analysis due to the
following reasons: missing heart rate (n=4), prevalent myocar-
dial infarction (n=215), prevalent heart failure (n=58), use of
medications affecting heart rate, including b-blockade, calcium
channelblockade,digoxin,orotherantiarrhythmicmedications
(n=780),prevalentatrialﬁbrillation(n=22),previouspermanent
pacemakerinsertion(n=9),atrioventriculardissociationonECG
(n=2), or missing covariates (n=271). After these exclusions,
4058 participants remained eligible for the present analysis.
Participants provided informed consent, and the study was
approvedbytheInstitutionalReviewBoardatBostonUniversity
Medical Center.
Clinical Assessment
All participants underwent routine history, physical examina-
tion, anthropometry, and laboratory assessment. Heart rate
was measured using standard supine 12-lead electrocardiog-
raphy at a paper speed of 25 mm/s, which was performed
after approximately 5 minutes of resting quietly. Seated blood
pressure was measured after at least 5 minutes of rest using
mercury sphygmomanometry and reported as the average of
2 physician-obtained readings. Diabetes mellitus was deﬁned
as a fasting glucose level ≥126 mg/dL, nonfasting blood
glucose level ≥200 mg/dL, or the use of insulin or oral
hypoglycemic medications. Participants who regularly smoked
cigarettes during the prior year were considered current
smokers. Electrocardiographic left ventricular hypertrophy
was deﬁned using standard ECG criteria.
18 Valvular heart
disease was deﬁned as a systolic murmur grade ≥3/6 or any
diastolic murmur auscultated on physician examination.
Baseline physical activity was assessed by using an admin-
istered questionnaire. A physical activity index composite
score was calculated based on the sum of usual reported
activity at a certain level within a 24-hour period, weighted
based on estimated oxygen consumption required for a given
activity level.
19,20 Fasting total and high density lipoprotein
cholesterol levels were obtained. The presence of atrial
ﬁbrillation was determined after examining all available ECGs
from FHS clinic visits and medical records.
Deﬁnition of Cardiovascular Outcome Events
FHS participants were monitored regularly for the occurrence
of cardiovascular events and death. Cardiovascular events
were adjudicated by a panel of 3 physicians after review of
medical records. Heart failure was deﬁned based on FHS
criteria.
21 A major cardiovascular disease event was deﬁned
as myocardial infarction, coronary insufﬁciency (prolonged
ischemic symptoms with new ECG abnormalities in the
absence of biomarker elevations indicative of infarction),
heart failure, stroke, or cardiovascular death.
22 For analyses
examining cardiovascular disease, participants with prevalent
disease were excluded (n=39).
Statistical Analysis
Cross-sectional correlates of baseline heart rate were deter-
mined using multivariable linear regression. The associations
of baseline resting heart rate and incident cardiovascular
events were examined using multivariable proportional haz-
ards regression (Cox) models. Individuals who died were
censored for analyses of nonfatal events. Separate analyses
were conducted for incident cardiovascular disease, heart
failure, stroke, coronary heart disease, pacemaker implanta-
tion, all-cause death, and cardiovascular death. Models were
ﬁrst adjusted for age and sex and further adjusted for systolic
blood pressure (BP), use of antihypertensive medications, body
mass index (BMI), diabetes mellitus, smoking status, physical
activity index, valvular heart disease, ECG left ventricular
hypertrophy, total–to–HDL cholesterol ratio, minor cardiovas-
cular disease (angina, transient ischemic attack, and intermit-
tent claudication), PR interval, and QRS duration.
23,24 To
account for multiple hypothesis testing (7 outcomes), a
Bonferroni-corrected P-value of <0.007 was considered
signiﬁcant for primary analyses. We tested for proportionality
of hazards for each outcome by ﬁtting an interaction term of
follow-up time and heart rate and by visually checking
Martingale-based residuals. Proportionality of hazards was
conﬁrmed for all outcomes. The cumulative incidence of each
of the clinical outcomes across heart rate quartiles was
examined using a Kaplan–Meier-like method while accounting
for competing risk of death.
25 A sensitivity analysis was
conducted after exclusion of individuals with minor cardiovas-
cular disease at baseline, including angina, transient ischemic
attack, intermittent claudication, and valvular heart disease.
In secondary analyses, we tested for differential risk
associated with heart rate for heart failure versus non–heart
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Hfailure cardiovascular disease using the Lunn–McNeil
method.
26 The association of sex-speciﬁc heart rate quartiles
and primary events was examined using Cox models. To
evaluate possible nonlinear relationships in secondary analy-
ses, we ﬁtted restricted cubic splines with 3 knots at 25th,
50th, and 75th percentiles. We formally tested for age9heart
rate and sex9heart rate interaction terms. Given recent data
showing a differential effect of heart rate on heart failure in
men and women,
27 we performed secondary analyses strat-
iﬁed by sex. We conducted analyses using mean heart rate
across the preceding 3 exam cycles spanning approximately
8 years prior to the baseline examination (original cohort
exams 16, 18, and 20 and offspring cohort exams 2, 3, and 4).
We examined the effect of heart rate as a time-dependent
variable over 8 years following the baseline exam as a
predictor of outcomes. In secondary analyses, we examined
the association of heart rate and clinical outcomes in
participants taking heart rate–modifying agents at the base-
line examination (b-blockers, calcium channel blockers). All
analyses were conducted using SAS, version 9.3 (SAS
Institute, Cary, NC).
Results
The baseline characteristics of 4058 participants (mean age
55 years, 56% women) are displayed in Table 1. Baseline
resting heart rate was 6411 bpm in men, and 6711 bpm
in women. Older age, female sex, higher diastolic BP, higher
BMI, diabetes, smoking, and lower HDL cholesterol were all
associated with higher resting heart rate (P<0.05 for all,
Table 2). Higher physical activity as measured by the physical
activity index was associated with a small but signiﬁcant
decrease in resting heart rate in age- and sex-adjusted
analyses (0.56 bpm decrease per 1-standard deviation [SD]
increase in physical activity index, P=0.001) and remained a
correlate of baseline heart rate after multivariable adjustment
(0.56-bpm decrease, P=0.001). In comparison, each 1-SD
increase in diastolic BP was associated with a 2-bpm increase
in heart rate (P<0.0001).
During a median follow-up of 19 years, 708 participants
developed incident cardiovascular disease. Speciﬁc cardio-
vascular events included 303 participants with incident heart
failure, 343 participants with coronary heart disease, and 216
participants with stroke. An additional 48 participants under-
went permanent pacemaker insertion. There were 1186
deaths, of which 252 were classiﬁed as cardiovascular death.
Baseline Heart Rate Predicts Cardiovascular
Events
The cumulative incidence of cardiovascular disease, heart
failure, and death increased across sex-speciﬁc heart rate
Table 1. Baseline Characteristics of FHS Participants by Heart Rate Quartile
Heart Rate Quartile
Q1
(n=918)
Q2
(n=1077)
Q3
(n=998)
Q4
(n=1065)
Age, y 52 (12) 54 (13) 56 (13) 59 (15)
Women, n (%) 491 (53) 626 (58) 586 (59) 586 (55)
Systolic blood pressure, mm Hg 124 (20) 128 (19) 129 (20) 135 (21)
Diastolic blood pressure, mm Hg 76 (10) 78 (10) 79 (10) 81 (11)
Heart rate, beats per minute 52 (4) 61 (2) 68 (3) 80 (8)
Body mass index, kg/m
2 25.6 (3.9) 26.2 (4.4) 26.9 (5.0) 27.4 (5.3)
Antihypertensive treatment, n (%) 81 (9) 120 (11) 140 (14) 229 (22)
Diabetes mellitus, n (%) 13 (1) 33 (3) 44 (4) 96 (9)
Current smoker, n (%) 146 (16) 240 (22) 248 (25) 304 (29)
Left ventricular hypertrophy, n (%) 9 (1) 9 (1) 22 (2) 19 (2)
Valvular heart disease, n (%) 7 (1) 8 (1) 14 (1) 43 (4)
Physical activity index 37 (7) 37 (7) 36 (7) 36 (7)
Total cholesterol, mg/dL 200 (38) 206 (37) 208 (38) 212 (41)
HDL cholesterol, mg/dL 53 (14) 52 (15) 50 (15) 48 (16)
Values are means (SD) unless otherwise speciﬁed. Heart rate cut-offs for men are: 25th percentile=55 bpm, 50th percentile=61 bpm, 75th percentile=69 bpm; for women:
25th percentile=59 bpm, 50th percentile=65 bpm, 75th percentile=74 bpm. FHS indicates Framingham Heart Study; HDL, high-density lipoprotein.
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Hquartiles (Figure 1). Baseline resting heart rate predicted
incident cardiovascular disease (Table 3). In multivariable-
adjusted analyses (including adjustment for physical activity),
each 1-SD (11 bpm) increase in baseline heart rate was
associated with a 15% increased risk of cardiovascular
disease (adjusted hazard ratio [HR] 1.15, 95% CI 1.07 to
1.24, P=0.0002). When individual components of cardiovas-
cular disease were examined, this association appeared most
pronounced for incident heart failure events, with each 1-SD
increase in baseline heart rate associated with a 32%
increased risk of future heart failure (adjusted HR 1.32, 95%
CI 1.18 to 1.48, P<0.0001). Speciﬁcally, there was a
differential effect of heart rate on heart failure compared
with non–heart failure cardiovascular disease (P=0.004 for
difference).
When examined across sex-speciﬁc quartiles of heart rate,
individuals in the top quartile had a 2-fold increased risk of
heart failure (adjusted HR 2.04, 95% CI 1.38 to 3.01, P for
trend across quartiles <0.0001). Resting heart rate was
associated with higher risk of coronary heart disease and
stroke in age- and sex-adjusted analyses, but that association
was attenuated after multivariable adjustment (Table 3).
Similar results were obtained when examining heart rate by
sex-speciﬁc quartiles.
In contrast to the increased risk of conventional cardio-
vascular events, higher heart rate was associated with a 40%
decreased risk of requiring permanent pacemaker placement
(per 1-SD increase in heart rate, adjusted HR 0.55, 95% CI
0.38 to 0.79, P=0.001).
Baseline Heart Rate Predicts All-Cause Mortality
Resting heart rate predicted increased risk of all-cause
mortality, with each 1-SD increase in heart rate associated
with a 17% increased risk of all-cause death (multivariable-
adjusted hazard ratio 1.17, 95% CI 1.11 to 1.24, P<0.0001,
Table 3). Resting heart rate predicted cardiovascular
death, with each 1-SD increase in heart rate associated
with a 18% increased risk (adjusted HR 1.18, 95% CI 1.04 to
1.33, P=0.01), although this association did not meet the
Bonferroni-corrected P-value threshold of P<0.007.
Effect Across Heart Rate Range
Restricted cubic splines were used to model the effect of
heart rate on clinical outcomes. A lower heart rate appeared
to be associated with lower risk of cardiovascular disease,
heart failure, and death, even at very low heart rates
<60 bpm. There were no signiﬁcant nonlinear terms, and ﬁt
statistics of the spline analyses did not suggest a lower
threshold beyond which the beneﬁt of a lower heart rate
abated or increased (Figure 2).
Secondary Analyses
After additionally excluding individuals with prevalent minor
cardiovascular disease and valvular disease (n=281), results
were not materially different from primary results (Table 4).
We formally tested for interactions of age and sex with heart
Table 2. Cross-sectional Correlates of Baseline Resting Heart Rate
Multivariable-Adjusted Model*
Estimate (SE) P Value
Age, per 14 y 0.16 (0.02) <0.0001
Female sex 5.16 (0.38) <0.0001
Systolic blood pressure, per 20 mm Hg 0.54 (0.27) 0.046
Diastolic blood pressure, per 10 mm Hg 2.12 (0.24) <0.0001
Body mass index, per 5 kg/m
2 0.65 (0.20) 0.001
Antihypertensive treatment 1.56 (0.52) 0.003
Diabetes mellitus 6.59 (0.82) <0.0001
Current smoker 3.38 (0.40) <0.0001
Left ventricular hypertrophy 0.33 (1.43) 0.82
Valvular heart disease 5.80 (1.28) <0.0001
Physical activity index, per 7 units 0.56 (0.17) 0.001
Total cholesterol, per 39 mg/dL 0.27 (0.17) 0.12
HDL cholesterol, per 15 mg/dL 0.75 (0.19) <0.0001
HDL indicates high-density lipoprotein.
*Multivariable model includes all covariates listed in table. Estimate represents change in baseline heart rate per 1-SD change in continuous variables (as noted) or the presence vs
absence of dichotomous variables.
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Hrate. There was no effect modiﬁcation by sex (P>0.05 for all
outcomes), and when examined separately in men and
women, heart rate remained associated with incident cardio-
vascular disease, heart failure, and all-cause and cardiovas-
cular death. In contrast, age appeared to modify the
association of resting heart rate and heart failure outcomes
(P=0.03). Speciﬁcally, the association of resting heart rate
and incident heart failure events was less pronounced at older
ages. There was no effect modiﬁcation by age for cardiovas-
cular disease, death, or pacemaker events.
Average heart rate over approximately 8 years preceding
the baseline examination remained a signiﬁcant predictor of
cardiovascular disease, heart failure, death, and need for
permanent pacemaker implantation. When examined as a
time-dependent variable over the course of 8 years, the
association with pacemaker implantation was no longer
signiﬁcant, whereas the association with coronary heart
disease remained signiﬁcant even after multivariable adjust-
ment (Table 5).
In secondary analyses examining the association of heart
rate and clinical outcomes in participants taking heart rate–
modifying agents at the baseline examination (n=575), we
found similar trends as in the primary analysis for all
outcomes except pacemaker insertion. After multivariable
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Figure 1. Heart rate quartiles and risk of long-term cardiovascular events. Cumulative incidence of clinical events increases across
sex-speciﬁc heart rate quartiles for cardiovascular events (A), heart failure (B), and all-cause mortality (C). Analyses for nonfatal events
were adjusted for competing risk of death. Heart rate cut-offs for men are 25th percentile=55 bpm, 50th percentile=61 bpm, 75th
percentile=69 bpm; for women: 25th percentile=59 bpm, 50th percentile=65 bpm, and 75th percentile=74 bpm. CVD indicates
cardiovascular disease; HF, heart failure.
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Figure 2. Restricted cubic spline plots, showing the association of heart rate and clinical outcomes for cardiovascular disease (A),
heart failure (B), and all-cause mortality (C). Three knots were placed at the 25th, 50th, and 75th percentiles of heart rate, and
dashed lines represent 95% CIs.
Table 3. Association of Baseline Resting Heart Rate and Cardiovascular Outcomes
Age/Sex-Adjusted Model Multivariable-Adjusted Model*
HR (95% CI) P Value HR (95% CI) P Value
Primary outcomes
Cardiovascular disease (708 events) 1.29 (1.20 to 1.39) <0.0001 1.15 (1.07 to 1.24) 0.0002
Heart failure (303 events) 1.46 (1.31 to 1.62) <0.0001 1.32 (1.18 to 1.48) <0.0001
Coronary heart disease (343 events) 1.26 (1.14 to 1.40) <0.0001 1.08 (0.96 to 1.20) 0.20
Stroke (216 events) 1.22 (1.07 to 1.39) 0.003 1.10 (0.96 to 1.26) 0.19
Secondary outcomes
Pacemaker (48 events) 0.53 (0.37 to 0.75) 0.0003 0.55 (0.38 to 0.79) 0.001
Death (1186 events) 1.26 (1.19 to 1.33) <0.0001 1.17 (1.11 to 1.24) <0.0001
Cardiovascular death (252 events) 1.34 (1.19 to 1.51) <0.0001 1.18 (1.04 to 1.33) 0.01
HDL indicates high-density lipoprotein; HR, hazard ratio per 1-SD increase in heart rate.
*Multivariable analyses adjusted for age, sex, systolic blood pressure, use of antihypertensive treatment, body mass index, diabetes, smoking status, physical activity index, valvular heart
disease, electrocardiographic left ventricular hypertrophy, total/HDL cholesterol ratio, minor cardiovascular disease, and PR and QRS duration.
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remained signiﬁcantly associated with heart rate (P<0.0001,
and P=0.02, respectively).
Discussion
Our study demonstrates that individuals with a higher heart
rate have an excess risk of cardiovascular events and
mortality, even after accounting for clinical risk factors and
physical activity. The association with future events is
particularly strong for heart failure, with individuals in the
highest quartile of heart rate having a 2-fold increased risk of
incident heart failure. In contrast, we found that lower heart
rate was associated with a greater risk of future permanent
pacemaker implantation.
Existing community-based studies have focused largely on
fatal events of on individuals with existing cardiovascular
disease.
1,2,10,12,28 We now extend these data to a compre-
hensive assessment of fatal and nonfatal cardiovascular
outcomes in a contemporary sample with extensive assess-
ment of cardiovascular risk factors. In contrast to prior
community-based studies,
29 we were able to exclude partic-
ipants with prevalent cardiovascular disease and those taking
heart rate–modifying medications at baseline.
Our ﬁndings suggest that the association of heart rate
with cardiovascular disease is driven largely by incident
Table 4. Association of Baseline Resting Heart Rate and Cardiovascular Outcomes After Exclusion of Prevalent Minor
Cardiovascular Disease and Valvular Disease
Age/Sex-Adjusted Model Multivariable-Adjusted Model*
HR (95% CI) P Value HR (95% CI) P Value
Primary outcomes
Cardiovascular disease (593 events) 1.29 (1.19 to 1.39) <0.0001 1.15 (1.06 to 1.25) 0.0007
Heart failure (233 events) 1.45 (1.29 to 1.64) <0.0001 1.34 (1.18 to 1.52) <0.0001
Coronary heart disease (285 events) 1.26 (1.12 to 1.40) <0.0001 1.07 (0.95 to 1.21) 0.26
Stroke (188 events) 1.24 (1.08 to 1.42) 0.003 1.11 (0.96 to 1.28) 0.17
Secondary outcomes
Pacemaker (37 events) 0.47 (0.31 to 0.72) 0.0004 0.50 (0.33 to 0.77) 0.002
Death (987 events) 1.26 (1.19 to 1.34) <0.0001 1.20 (1.12 to 1.28) <0.0001
Cardiovascular death (188 events) 1.32 (1.15 to 1.51) <0.0001 1.17 (1.01 to 1.35) 0.03
HDL indicates high-density lipoprotein; HR, hazard ratio per 1 standard deviation increase in heart rate.
*Multivariable analyses adjusted for age, sex, systolic blood pressure, use of antihypertensive treatment, body mass index, diabetes, smoking status, physical activity index,
electrocardiographic left ventricular hypertrophy, total/HDL cholesterol ratio, and PR and QRS duration.
Table 5. Heart Rate as a Time-Dependent Variable as a Predictor of Clinical Outcomes
Age/Sex-Adjusted Model Multivariable-Adjusted Model*
HR (95% CI) P Value HR (95% CI) P Value
Primary outcomes
Cardiovascular disease (708 events) 1.31 (1.22 to 1.40) <0.0001 1.22 (1.13 to 1.30) <0.0001
Heart failure (303 events) 1.51 (1.37 to 1.67) <0.0001 1.41 (1.27 to 1.56) <0.0001
Coronary heart disease (343 events) 1.31 (1.19 to 1.44) <0.0001 1.19 (1.08 to 1.32) 0.0004
Stroke (216 events) 1.13 (0.99 to 1.28) 0.06 1.06 (0.93 to 1.20) 0.40
Secondary outcomes
Pacemaker (48 events) 0.90 (0.67 to 1.20) 0.46 0.99 (0.75 to 1.33) 0.97
Death (1186 events) 1.23 (1.16 to 1.29) <0.0001 1.18 (1.12 to 1.25) <0.0001
Cardiovascular death (252 events) 1.27 (1.13 to 1.42) <0.0001 1.18 (1.05 to 1.32) 0.005
HDL indicates high-density lipoprotein; HR, hazard ratio per 1 standard deviation increase in heart rate.
*Multivariable analyses adjusted for age, sex, systolic blood pressure, use of antihypertensive treatment, body mass index, diabetes, smoking status, physical activity index, valvular heart
disease, electrocardiographic left ventricular hypertrophy, total/HDL cholesterol ratio, minor cardiovascular disease, and PR and QRS duration.
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Hheart failure. Two recent population-based studies sug-
gested an association of heart rate with heart failure
in men but not women after exclusion of individuals
taking heart rate–modifying medications,
27,30 though our
data suggest that the ﬁnding is equally prominent in both
sexes. Our cohort was on average more than 10 years
younger than individuals in the Rotterdam Study; this
difference may have given us greater statistical power,
because we found that the association weakened with
advancing age.
Interestingly, we found that resting heart rate captured at a
single examination was as strong a predictor of cardiovascular
outcomes as repeated measurements of heart rate averaged
over the course of 8 years. This highlights the potential role of
resting heart rate as an easily obtainable measure of
cardiovascular prognosis.
We also present novel population-based data regarding
the higher risk of future pacemaker implantation with lower
heart rates, an association that was independent of other
risk factors, including PR interval and QRS duration.
23,24
Asymptomatic bradycardia has been associated with higher
rates of pacemaker implantation in a clinical cohort of older
patients.
31 As such, sinus bradycardia may precede
advanced conduction system and cardiac disease, which
may be associated with an adverse prognosis. Indeed, some
studies have demonstrated increased mortality with lower
heart rates and a J-shaped relationship of heart rate and
outcomes in elderly community-dwelling adults and in
individuals with existing cardiovascular disease.
28,32–34
Despite the increase in risk of permanent pacemaker
implantation at lower heart rates, we found no evidence
of concomitant increase in mortality or cardiovascular
disease with bradycardia; to the contrary, our spline curves
suggest continued beneﬁt with regard to cardiovascular
disease at lower heart rates. It may be that bradycardia
portends increased overall risk in the elderly or in those
with existing cardiovascular disease, whereas bradycardia in
ostensibly healthy individuals is protective with regard to
overall prognosis despite an increased risk of pacemaker
implantation.
The mechanism by which increased heart rate predicts
adverse cardiovascular outcomes is likely multifactorial. On
one hand, heart rate may directly affect cardiovascular risk:
previous studies have shown that higher heart rate may have
proatherogenic effects by increasing shear stress,
7 and higher
heart rate has been associated with progression of athero-
sclerosis.
35 Higher heart rate also has negative effects on
myocardial energetics,
8 which supports the particularly pro-
nounced effect on heart failure outcomes. On the other hand,
heart rate may reﬂect other underlying processes leading to
adverse outcomes. For instance, elevated heart rate may
reﬂect autonomic dysfunction and increased sympathetic
activity.
6 Higher heart rate has also been shown to precede
the development of diabetes mellitus.
5 Finally, higher heart
rate could reﬂect poorer physical ﬁtness.
36 However, associ-
ations in our study persisted despite adjustment for physical
activity. We found a strong association with cardiovascular-
speciﬁc outcomes and all-cause mortality, suggesting that
heart rate may be both mediator of cardiovascular risk, as well
as a marker of overall poor prognosis. Further studies are
needed to evaluate underlying mechanisms by which heart
rate may lead to adverse outcomes.
Several limitations deserve mention. Ours is an observa-
tional study, and thus the ability to make causal inferences is
limited. Generalizability of our results must also be inter-
preted with caution given our predominantly white sample.
Given the modest number of permanent pacemaker implants
during follow-up, inferences about potential interactions of
heart rate and age are not conclusive. Finally, the clinical
implications our ﬁndings will need to be explored further.
Heart rate could be a highly reproducible and routinely
obtained measure that might serve in risk-stratiﬁcation of
patients.
In summary, we show that increased heart rate is
associated with elevated cardiovascular risk and increased
mortality in a community-based sample. Conversely, lower
heart rate is associated with a greater risk of future
permanent pacemaker implantation. These associations
appeared to be independent of physical activity and other
potential confounding factors. Whether treatment aimed at
lowering heart rate in individuals without existing cardiovas-
cular disease might reduce cardiovascular risk, as has been
shown in patients with chronic heart failure,
37 remains to be
seen.
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